SGLT2 inhibitors represent one of the most remarkable therapeutic developments in heart failure care, transitioning from ...
SGLT-2 inhibitors were linked to lower risk for autoimmune rheumatic diseases in those with diabetes compared with sulfonylureas.
Angiotensin receptor-neprilysin inhibitors (ARNIs) represent a significant advancement in heart failure therapy, combining an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback